Allernix

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allernix

Property Description
Active ingredient Diphenhydramine Hydrochloride
Form Tablet, Caplet, Capsule, Liquid, Cream
Pharmacological class First-generation H1-Antihistamine
Common use Allergy symptom relief, occasional sleep aid
Origin Synthetic

Allernix: Classification and Active Composition

Allernix is the trade name for a medication centered on the active compound Diphenhydramine, generally present as Diphenhydramine Hydrochloride, which is defined as a synthetic compound and a first-generation H1-antihistamine belonging to the ethanolamine class. This medication is typically marketed as a single-ingredient product, often available over-the-counter (OTC).

The designation as a first-generation agent is critical because it highlights the medication’s ability to affect the central nervous system, resulting in a distinct calming effect. This specific property is why the drug is widely recognized beyond allergy relief for both its antihistaminic and sedative properties.

What Type of Medication is Diphenhydramine?

Diphenhydramine functions primarily as an H1 receptor antagonist, meaning its core mechanism is centered on preventing the body's natural substance, histamine, from binding to H1 receptors. The compound also possesses significant anticholinergic activity, which plays a role in regulating various fluid secretions.

The overall purpose of Allernix is to provide relief by blocking the biological actions of histamine released during allergic episodes, thereby managing related discomfort. The combined action of histamine blocking and the associated drying effect helps manage common symptoms, such as the persistent runny nose that can accompany seasonal allergies.

Common Forms and General Use

Allernix is offered in diverse pharmaceutical preparations intended for oral administration, most commonly including oral solids such as tablets and capsules, alongside oral liquids like syrup or elixir. For non-systemic use, there are also specialized topical preparations, such as creams or gels, as well as prescription-only injectable solutions for controlled clinical settings.

The availability across various dosage forms ensures the medication can be administered based on patient needs, such as a liquid being suitable for pediatric patients. The overall general purpose is to reduce common allergic symptoms such as sneezing, itching, and fluid discharges like a runny nose, achieved through its combined histamine blocking and drying effect.

What side effects are possible with Allernix?

Possible Side Effects and Safety Information

The safety profile of Allernix (Diphenhydramine Hydrochloride) is defined by its effects on the Central Nervous System (CNS) and its anticholinergic properties, as classified in official regulatory documents. Adverse reactions are systematically grouped by frequency and the body system affected.

Adverse Reaction Frequencies and System Involvement

Adverse reactions are classified according to regulatory standards (e.g., EMA/ICH frequency bands):

  • Common Reactions (>1/100 to <1/10): Typically involve the nervous system, including drowsiness, sedation, dizziness, disturbance in attention, and unsteadiness. Anticholinergic effects such as dry mouth are also common.
  • Uncommon Reactions (>1/1000 to <1/100): Include reactions like agitation, confusion, palpitations, blurred vision, nausea, and urinary retention.

System-organ classes involved include Nervous System Disorders, Gastrointestinal Disorders, Cardiac Disorders, and Renal and Urinary Disorders.

Clinically Significant and Population-Specific Safety

Official labeling documents certain serious adverse reactions, which are typically rare but clinically important, such as anaphylactic shock, convulsions, and rare blood disorders like agranulocytosis.

Specific safety considerations are documented for different populations:

  • Older Adults: Individuals aged 60 and over are documented as being more likely to experience adverse effects such as dizziness, hypotension, and confusion.
  • Pediatric Patients: May experience a different reaction, sometimes exhibiting paradoxical excitation (agitation or restlessness) rather than the expected sedation.

Safety constraints and necessary caution are advised in situations that may be exacerbated by the drug’s properties, including patients with narrow-angle glaucoma or conditions causing obstruction, such as symptomatic prostatic hypertrophy or pyloroduodenal obstruction.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Allernix (Diphenhydramine Hydrochloride) may present with a range of documented clinical manifestations, primarily affecting the Central Nervous System (CNS) and exhibiting signs of anticholinergic toxicity. Documented CNS effects span from profound drowsiness, somnolence, and ataxia to paradoxical excitement, restlessness, and agitation. Anticholinergic signs include mydriasis (dilated pupils), dry mouth, urinary retention, and hyperpyrexia (fever).

Officially recognized severe or life-threatening outcomes require urgent intervention. These complications include cardiac arrhythmias, generalized seizures (convulsions), respiratory depression, and progression to coma or cardiovascular collapse. Regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose event. Individuals experiencing severe signs, such as difficulty breathing or unresponsiveness, must contact emergency services.

Officially Documented Management
Emergency Action: Seek immediate medical attention
Antidote Status: No specific antidote is known
Monitoring Requirement: Continuous Electrocardiogram (ECG) monitoring is required

Hospital observation is necessary until the patient's condition is stable. Regulatory documents note that children are more susceptible to CNS excitation and convulsions, while elderly patients may exhibit a greater degree of anticholinergic effects, such as confusion.

Therapeutic Uses of Allernix

What Allernix Treats: Main Uses and Benefits

Allernix is commonly applied in clinical settings that involve acute or unstable symptom patterns associated with seasonal and environmental allergies. The medication is used for managing symptoms related to heightened physiological activity, such as persistent sneezing, excessive runny nose (rhinorrhea), and troublesome itching (pruritus). This provides supportive relief that contributes to easing the overall symptom load during periods of heightened discomfort.

The medication is applied in addressing symptom clusters such as: allergy symptoms, transient insomnia, motion sickness, and minor skin irritation.

Support for Sleep and Motion Management

The medication is commonly used to help with transient insomnia or difficulty initiating sleep in situations involving temporary factors. It supports the patient during difficult episodes by easing distress and assisting with rest, helping to maintain a sense of stability when symptoms are more noticeable. Allernix may also assist with managing the symptoms of motion sickness, which can affect functional stability by helping to ease associated nausea and dizziness, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Pruritus and Secretions
Symptom Management: This medication is considered relevant for easing symptomatic discomfort related to both itching (pruritus) and excessive fluid secretions (runny nose) common in allergic and cold symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Profile for Allernix (Diphenhydramine)

Regulatory documents establish specific rules defining who can and cannot use Allernix, which is the trade name for Diphenhydramine. These rules govern absolute prohibitions, age restrictions, and conditional use based on pre-existing medical conditions.


Absolute Contraindications

Use is strictly contraindicated for neonates and premature infants, as well as for nursing mothers (breastfeeding women). Individuals with a documented hypersensitivity to diphenhydramine or other chemically similar antihistamines must not use this medicine.

Age- and Condition-Based Restrictions

Allernix is approved for use in adults and children 12 years of age and older. However, use is generally not recommended for children younger than 6 years and should be avoided by older adults (65 years and older) due to the heightened risk of adverse effects. Conditional use requires caution in patients with conditions such as angle-closure glaucoma, prostatic hypertrophy (enlarged prostate), stenosing peptic ulcer, or bronchial asthma. Use during pregnancy is conditional, and the medication is not recommended during the last two weeks of pregnancy.

What should I know about interactions with other medicines?

Allernix Interactions with other medicines and products

It is important to inform a healthcare provider or pharmacist of all medications and supplements being taken, including prescription, over-the-counter (OTC) drugs, and herbal remedies. Drug interactions can potentially alter the effectiveness of Allernix or increase the risk of side effects.

Increased Sedation Risk

The primary concern when taking Allernix (which contains diphenhydramine) is an increased risk of central nervous system (CNS) depression, leading to heightened drowsiness, dizziness, and impaired concentration. This effect is significantly amplified when Allernix is combined with other substances that also cause sedation. It is strongly advised to avoid or use caution with the following:

  • Alcohol: Consumption should be avoided as it can severely intensify CNS depression and impairment.
  • Other Sedatives: This includes tranquilizers, sleeping medications (hypnotics), and certain medications for anxiety.
  • Opioid Pain Medications: Combining Allernix with opioids can increase the risk of respiratory depression and severe sedation.
  • Muscle Relaxants and Certain Antipsychotics/Antidepressants: These medications may heighten the sedative effects of Allernix.

Anticholinergic Effects

Allernix has anticholinergic properties. Using it with other medications that also block acetylcholine (anticholinergics), such as certain drugs for Parkinson's disease, bladder control, or certain antidepressants, can worsen side effects like dry mouth, constipation, confusion, and difficulty urinating, particularly in older adults.

Other Antihistamines

Do not take Allernix with other antihistamines, including those found in common OTC cough, cold, or sleep-aid products, as this can lead to an overdose of the same class of medication and significantly increase the risk and severity of adverse effects.

Mechanism of Action

Allernix, containing Desloratadine, functions as a second-generation H1-receptor inverse agonist and competitive antagonist, primarily targeting peripheral tissues. The molecule exhibits a selective, high-affinity binding interaction with the histamine H1 receptors located on the surface of endothelial cells, respiratory smooth muscle, and immune cells such as mast cells. By binding to the H1 receptor, the drug prevents the binding and constitutive activity of the endogenous mediator histamine.

This blockade of the H1 receptor prevents the Gq protein-coupled signaling cascade that is typically activated by histamine. Downstream, this modulates cellular responses including the prevention of histamine-induced IP3 (inositol triphosphate) generation and the subsequent rise in intracellular calcium concentration. The system-level physiological consequence of this inhibition is a reduction in capillary permeability and the corresponding prevention of histamine-induced tissue edema and vasodilation in targeted peripheral vascular beds.

Dosage and Administration Information

The use of Allernix (Diphenhydramine) involves specific parameters related to the route of administration, dose, frequency, and patient population. The medicine is available for systemic relief via oral administration (tablets, capsules, liquid), and for local use via topical preparations. For clinical settings, it is also available as a parenteral solution for Intramuscular (IM) or Intravenous (IV) injection.

Standard Adult Dosing

The standard adult oral dose for general use is typically 25 mg to 50 mg every 4 to 6 hours as needed. The total oral dose must not exceed 300 mg in a 24-hour period. When used for the specific indication of occasional sleep difficulty, the dose is typically 50 mg taken once daily, approximately 30 minutes before bedtime. For the prevention of motion sickness, the initial dose is generally administered about 30 minutes before exposure to motion.

Population and Administration Rules

In older adults (geriatric patients), it is common practice to start with a lower initial dose due to potential increased sensitivity. Pediatric dosing is based on body weight or age; for children aged 6 to 11, the oral dose is typically 12.5 mg to 25 mg every 4 to 6 hours, with a maximum daily limit of 150 mg.

For clinical administration via the IV route, the rate of injection is a critical procedural constraint and must generally not exceed 25 mg per minute. In the event of a missed oral dose, the standard approach is to take the dose when remembered, while maintaining the minimum 4- to 6-hour interval before taking the next dose and avoiding a double dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Allernix

Evidence for Acute Symptom Management

This section will summarize findings from controlled clinical trials and systematic reviews that examined the compound’s role in research exploring outcomes related to seasonal allergy symptoms, localized pruritus, and symptoms related to motion.

Clinical Trials for Allergic Rhinitis and Urticaria

The research base for this application primarily consists of short-term, double-blind Randomized Controlled Trials (RCTs) and systematic reviews. Studies explored how symptoms change over time and measured outcomes related to physical discomfort associated with allergy symptoms such as sneezing, persistent runny nose (rhinorrhea), and troublesome itching (pruritus). Research examined the compound's effect on objective outcomes by monitoring outcomes related to histamine exposure, such as wheal and flare measurements. Populations studied included adults and children (systemic use ge2 years). Studies consistently included assessments of psychomotor performance as an outcome evaluated in the observed populations.

Research on Motion Sickness

Research examined temporary physiological imbalance by monitoring patient-reported outcomes describing perceived discomfort, specifically the compound’s role in research exploring the occurrence of nausea and dizziness during motion exposure. Trials reported measurements of symptom intensity scores when the compound was evaluated in this research context. Evidence remains limited and heterogeneous in research exploring the applicability of findings from controlled settings to varied environmental conditions.

Research for Short-Term Sleep Support

The research exploring this application includes Randomized, Placebo-Controlled Trials which were applied in studies examining patient-reported experiences related to difficulty initiating sleep. Studies monitored objective sleep parameters using polysomnography, such as sleep latency and efficiency, alongside patient-reported outcomes. Studies report patterns where the sedative effect appeared to change after continuous administration for one to two weeks. This suggests that certainty remains low concerning the patterns observed beyond the immediate short-term trial duration.

Research Gaps and Areas of Uncertainty

Evidence quality varies across studies, and several research limitations have been identified. For instance, comparative evidence is lacking for many common over-the-counter uses. Data are still emerging, and certainty remains low regarding the utility of the compound for long-term or chronic use across all indications. Findings describe group patterns, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Diphenhydramine Hydrochloride Injection, USP (FDA/Manufacturer Labeling)

Frequently Asked Questions (FAQ)

Common questions about Allernix (FAQ)


Q: How does Allernix compare generally to older allergy drugs?

Official information classifies Allernix (Diphenhydramine) as a first-generation H1-antihistamine. This categorization highlights that the medicine is known to affect the central nervous system and is associated with a distinct sedative effect, which is why it is also used as a temporary sleep aid.


Q: Is Allernix the same thing as Brand X or Brand Y?

Allernix is a specific trade name for the active ingredient Diphenhydramine. This active ingredient is common and is available under various other brand names across different products and formulations.


Q: Does Allernix interact with common pain relievers like ibuprofen?

Regulatory information indicates that Diphenhydramine is often combined with pain relievers, such as ibuprofen, in certain over-the-counter products. Regulatory bodies note that combining the two requires caution, primarily regarding the potential for toxic effects at higher doses.


Q: How quickly does Allernix typically start to work?

According to the official product information and pharmacokinetics data, a single oral dose of Diphenhydramine is generally absorbed quickly. The maximum concentration in the blood is typically reached in approximately one hour.


Q: What is the key difference between Allernix and competitor Z?

Allernix contains Diphenhydramine, which is a first-generation H1-antihistamine. Its main pharmacological characteristics are its ability to block histamine receptors alongside significant anticholinergic (drying) and sedative properties.


Q: Is Allernix suitable for people with pre-existing heart conditions?

Official labeling states that Diphenhydramine requires caution for use in patients who have a history of cardiovascular disease or high blood pressure. This is because the medicine has an action similar to atropine, and uncommon effects such as palpitations (irregular heartbeats) have been reported.


Q: Can Allernix interact with medications for high blood pressure?

Official documentation notes the need for caution when Diphenhydramine is used alongside medications for high blood pressure, particularly certain types such as alpha-1 adrenergic blockers. This combination may have additive effects on blood pressure, which could increase the potential for low blood pressure (hypotension) or dizziness upon standing.


Q: Is Allernix FDA-approved?

Yes, Diphenhydramine—the active ingredient in Allernix—is approved by the U.S. Food and Drug Administration (FDA). It is approved for indications including the treatment of allergy symptoms, prevention of motion sickness, and temporary sleep support.


Q: Is Allernix considered safe for people with liver or kidney issues?

The metabolism and elimination of Diphenhydramine primarily involve the liver and kidneys. Due to how the body processes the medicine, caution is required for individuals with liver disease or acute kidney issues, as regulatory bodies note the potential for altered processing in these populations.


Q: Does Allernix cause insomnia?

While the primary and most frequent effect of Allernix is sedation and sleepiness, insomnia (difficulty sleeping) is listed in official drug labeling as a possible adverse reaction.


Q: How long does the effect of one dose of Allernix last?

According to official product labeling and pharmacokinetic studies, the duration of activity for an average dose of Diphenhydramine is typically between four to six hours.


Q: What if I experience unusual mood changes while taking Allernix?

Official drug labeling notes various effects on the nervous system, including confusion, restlessness, and excitation. These types of effects have been documented, and they are particularly noted in pediatric patients or in cases of overdosage.


Q: Are there different strengths or forms of Allernix available?

Yes, Diphenhydramine is available in multiple forms, including oral solutions, tablets, capsules, creams, and injectable solutions. Common oral strengths generally available for use as an allergy treatment or sleep aid include 12.5 mg, 25 mg, and 50 mg.


Q: Are there any ingredients in Allernix that might trigger an allergic reaction itself?

Official guidance notes that the medicine must not be used by individuals with a known hypersensitivity to the active ingredient, Diphenhydramine. Like all medications, it also contains inactive ingredients (excipients), which may cause a reaction in individuals with specific sensitivities.


Q: Does Allernix affect the results of allergy skin tests?

Yes, Diphenhydramine is a strong antihistamine that can interfere with the results of a skin prick test by suppressing the skin's reaction to histamine. Regulatory guidance indicates that short-acting antihistamines are typically discontinued for a period (such as 48 hours) prior to a skin prick test to prevent false-negative results.

How should Allernix be stored and disposed of?

How to Store and Dispose of Allernix

Official Storage Requirements

Allernix (Diphenhydramine Hydrochloride) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat, moisture, and direct light.

The liquid formulation is explicitly restricted from being allowed to freeze. The medicine must be kept in its original container, which should remain tightly closed.

Handling and Child Safety

All forms of the medication are required to be stored out of the sight and reach of children to prevent accidental exposure.

Disposal Instructions

Unused or expired Allernix must be disposed of according to local regulations. Patients are advised to utilize a drug take-back program where available. Regulatory guidance requires that disposal via wastewater or drainage systems should be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Allernix found in:

A-Z Index: